M(o)TOR of pseudo-hypoxic state in aging: Rapamycin to the rescue
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
A groundbreaking publication by Sinclair and coworkers has illuminated the pseudo-hypoxic state in aging and its reversibility. Remarkably, these data also fit the mTOR-centered model of aging. Here we discuss that the mTOR pathway can cause cellular pseudo-hypoxic state, manifested by HIF-1 expression and lactate production under normoxia. We found that rapamycin decreased HIF-1 and lactate levels in proliferating and senescent cells in vitro. This reduction was independent from mitochondrial respiration: rapamycin decreased lactate production in normoxia, hypoxia, and in the presence of the OXPHOS inhibitor oligomycin. We suggest that pseudo-hypoxic state is not necessarily caused by mitochondrial dysfunction, but instead mitochondrial dysfunction may be secondary to mTOR-driven hyperfunctions. Clinical applications of rapamycin for reversing pseudo-hypoxic state and lactate acidosis are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“In particular, rapamycin extends life span in all experiments conducted in mice.(42-60) Furthermore, mTOR drives conversion of “young” cells to senescent phenotype, a process named geroconversion,(61-68) Rapamycin suppresses geroconversion, maintaining reversible state in cell culture(66-77) and in the organism.”
BackgroundExtending Healthy Life Span—From Yeast to Humans
Fontana, L., Partridge, L., & Longo, V. D. (2010) · Science · doi:10.1126/science.1172539 · Cited by 3,023 · cited 1×
“In agreement, genetic, environmental (calorie restriction), or pharmacological inhibition of TOR extends life span in yeast, flies, worms, and mammals.(12,21,26-41) In particular, rapamycin extends life span in all experiments conducted in mice.”
BackgroundmTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676 · cited 1×
“In agreement, genetic, environmental (calorie restriction), or pharmacological inhibition of TOR extends life span in yeast, flies, worms, and mammals.(12,21,26-41) In particular, rapamycin extends life span in all experiments conducted in mice.”
BackgroundGomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.037 · Cited by 1,482
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 1×
“The mTOR pathway stimulates HIF-1-α translation both under hypoxia and normoxia.(94-99) For example, either insulin or serum, which stimulates mTOR, induces HIF-1alpha in retinal pigmental epithelial (RPE) cells.”
BackgroundRibosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120 · cited 1×
“In agreement, genetic, environmental (calorie restriction), or pharmacological inhibition of TOR extends life span in yeast, flies, worms, and mammals.(12,21,26-41) In particular, rapamycin extends life span in all experiments conducted in mice.”
BackgroundmTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680
Replicative and chronological aging in Saccharomyces cerevisiae
Longo, V. D., Shadel, G. S., Kaeberlein, M., & Kennedy, B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.002 · Cited by 595 · cited 1×
“The period of time when yeast cells retain viability in the stationary culture is called chronological life span (CLS).(105) Rapamycin extends CLS of yeast culture.”
BackgroundDeletion of the mitochondrial superoxide dismutase sod-2 extends lifespan in Caenorhabditis elegans
Van Raamsdonk, J. M., & Hekimi, S. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000361 · Cited by 511 · cited 1×
“Several lines of evidence ruled out this point of view.(1-15) Instead, evidence emerges that aging is a continuation of cellular growth and function (hyperfunction), driven by signal transduction pathways such as mTOR.”
BackgroundRapamycin decelerates cellular senescence
Demidenko, Z. N., Zubova, S. G., Bukreeva, E. I., Pospelov, V. A., Pospelova, T. V., & Blagosklonny, M. V. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8606 · Cited by 391 · cited 2×
“Rapamycin partially suppressed geroconversion to the senescent phenotype.(69,91) As shown here rapamycin decreased production of lactic acid in senescent HT-p21 cells (Fig.”
BackgroundSelf-citationRapamycin extends murine lifespan but has limited effects on aging
Neff, F., Flores-Dominguez, D., Ryan, D. P., Horsch, M., Schröder, S., Adler, T., Afonso, L. C., Aguilar-Pimentel, J. A., Becker, L., Garrett, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67674 · Cited by 374
The overexpression of major antioxidant enzymes does not extend the lifespan of mice
Pérez, V. I., Van Remmen, H., Bokov, A., Epstein, C. J., Vijg, J., & Richardson, A. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2008.00449.x · Cited by 353 · cited 1×
“Several lines of evidence ruled out this point of view.(1-15) Instead, evidence emerges that aging is a continuation of cellular growth and function (hyperfunction), driven by signal transduction pathways such as mTOR.”
BackgroundRamos, F. J., Chen, S. C., Garelick, M. G., Dai, D.-F., Liao, C.-Y., Schreiber, K. H., MacKay, V. L., An, E. H., Strong, R., Ladiges, W. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003802 · Cited by 349 · cited 1×
“In particular, rapamycin extends life span in all experiments conducted in mice.(42-60) Furthermore, mTOR drives conversion of “young” cells to senescent phenotype, a process named geroconversion,(61-68) Rapamycin suppresses geroconversion, maintaining reversible state in cell culture(66-77) and in the organism.”
BackgroundOf mice and men: the benefits of caloric restriction, exercise, and mimetics
Mercken, E. M., Carboneau, B. A., Krzysik-Walker, S. M., & de Cabo, R. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2011.11.005 · Cited by 318
Iglesias-Bartolome, R., Patel, V., Cotrim, A., Leelahavanichkul, K., Molinolo, A. A., Mitchell, J. B., & Gutkind, J. S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.06.007 · Cited by 284 · cited 1×
“Furthermore, mTOR drives conversion of “young” cells to senescent phenotype, a process named geroconversion,(61-68) Rapamycin suppresses geroconversion, maintaining reversible state in cell culture(66-77) and in the organism.(43,78-81) mTOR-driven cellular senescence can be linked to stem cell exhaustion, agerelated d…”
BackgroundThe choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.
Korotchkina, L. G., Leontieva, O. V., Bukreeva, E. I., Demidenko, Z. N., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Aging · doi:10.18632/aging.100160 · Cited by 278 · cited 1×
“In contrast, when the cell cycle is arrested and growth-promoting pathways are still activated, then cells undergo senescence.(63-70) Cells grow in size and acquire senescent morphology.”
BackgroundSelf-citationParadoxical suppression of cellular senescence by p53
Demidenko, Z. N., Korotchkina, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002298107 · Cited by 273 · cited 2×
“In contrast, when the cell cycle is arrested and growth-promoting pathways are still activated, then cells undergo senescence.(63-70) Cells grow in size and acquire senescent morphology.”
BackgroundSelf-citationBlagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251
Self-citationCell cycle arrest is not senescence
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100281 · Cited by 217
Self-citationHypoxia suppresses conversion from proliferative arrest to cellular senescence
Leontieva, O. V., Natarajan, V., Demidenko, Z. N., Burdelya, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205690109 · Cited by 169 · cited 2×
“In contrast, when the cell cycle is arrested and growth-promoting pathways are still activated, then cells undergo senescence.(63-70) Cells grow in size and acquire senescent morphology.”
BackgroundSelf-citationCell senescence and hypermitogenic arrest
Blagosklonny, M. V. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor806 · Cited by 156
Self-citationAttenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence
Kolesnichenko, M., Hong, L., Liao, R., Vogt, P. K., & Sun, P. (2012) · Cell Cycle · doi:10.4161/cc.20683 · Cited by 123
Caveolin-1 and Accelerated Host Aging in the Breast Tumor Microenvironment
Mercier, I., Camacho, J., Titchen, K., Gonzales, D. M., Quann, K., Bryant, K. G., Molchansky, A., Milliman, J. N., Whitaker-Menezes, D., Sotgia, F., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.03.017 · Cited by 96 · cited 1×
“Furthermore, mTOR drives conversion of “young” cells to senescent phenotype, a process named geroconversion,(61-68) Rapamycin suppresses geroconversion, maintaining reversible state in cell culture(66-77) and in the organism.(43,78-81) mTOR-driven cellular senescence can be linked to stem cell exhaustion, agerelated d…”
BackgroundSelf-citationTOR-Driven Aging: Speeding Car Without Brakes
Blagosklonny, M. V. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10310 · Cited by 95 · cited 1×
“Cellular hyperfunctions cause alterations in homeostasis, age-related diseases, and organismal damage.(19-25) In agreement, genetic, environmental (calorie restriction), or pharmacological inhibition of TOR extends life span in yeast, flies, worms, and mammals.”
BackgroundSelf-citation
Cited by
Pastò, A., Bellio, C., Pilotto, G., Ciminale, V., Silic-Benussi, M., Guzzo, G., Rasola, A., Frasson, C., Nardo, G., Zulato, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2010 · Cited by 293
Sgarbi, G., Matarrese, P., Pinti, M., Lanzarini, C., Ascione, B., Gibellini, L., Dika, E., Patrizi, A., Tommasino, C., Capri, M., et al. (2014) · Aging · doi:10.18632/aging.100654 · Cited by 90
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Walters, H. E., & Cox, L. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082325 · Cited by 85
Chaube, B., Malvi, P., Singh, S. V., Mohammad, N., Meena, A. S., & Bhat, M. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6134 · Cited by 80
Fasting levels of hepatic p-S6 are increased in old mice
Leontieva, O. V., Paszkiewicz, G. M., & Blagosklonny, M. V. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949150 · Cited by 19
Self-citation
Metadata
- Authors
- Leontieva, O. V., & Blagosklonny, M. V.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2014-01-23
- Volume
- 13
- Issue
- 4
- Pages
- 509-515
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2038829197
- Cited by
- 46
- References
- 24
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.